Minimal residual disease (MRD) is a highly important prognostic indicator used to determine treatment efficacy in acute myeloid leukemia (AML) patients. Here, Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, discusses the benefits and disadvantages of the common techniques used to measure MRD today, including next-generation sequencing and flow cytometry. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
MRD detection techniques in AML: pros and cons
